OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Fox on the Design of the TERZO Trial of Duvelisib in R/R Nodal T-Cell Lymphoma

February 20th 2025

Christopher P. Fox, PhD, MBChB(Hons), FRCP FRCPath, discusses the TERZO trial investigating duvelisib in relapsed/refractory nodal T-cell lymphoma.

Dr Hernandez-Ilizaliturri on the Implications of Immunologic Changes With Venetoclax in CLL

February 19th 2025

Francisco J. Hernandez-Ilizaliturri, MD, details the clinical implications of venetoclax for the treatment of patients with CLL regarding T-cell repair.

Dr Vachhani on the Rationale for Evaluating Navtemadlin as a Ruxolitinib Add-On in Myelofibrosis

February 18th 2025

Pankit Vachhani, MD, discusses the rationale for evaluating navtemadlin as an add-on to ruxolitinib in myelofibrosis after a suboptimal response to ruxolitinib alone.

Dr Lee on the Real-World Safety Profile of Axi-Cel in R/R LBCL

February 18th 2025

Dasom (Caroline) Lee, MD, details the safety results of second-line axicabtagene ciloleucel in real-world patients with relapsed/refractory LBCL.

Dr Hijoka on Updated Efficacy Data With Everolimus Plus Lanreotide in GEP-NETs

February 18th 2025

Susumu Hijioka, MD, PhD, discusses the efficacy of first-line everolimus plus lanreotide in patients with unresectable or recurrent GEP-NETs.

Dr Pietrantonio on Amivantamab With/Without Chemotherapy in Right-Sided RAS/BRAF Wild-Type mCRC

February 18th 2025

Filippo Pietrantonio, MD, discusses updated efficacy with amivantamab as monotherapy and in combination with chemotherapy in metastatic colorectal cancer.

Dr Oh on the Development of Targeted Therapies in Prostate Cancer

February 17th 2025

William K. Oh, MD, highlights the evolution of targeted therapy for prostate cancer treatment, including antibody-drug conjugates and bispecific antibodies.

Dr Oluwole on CRS and Neurotoxicity Beyond 2 Weeks After Axi-Cel Infusion in R/R LBCL

February 17th 2025

Olalekan Oluwole, MD, MPH, discusses the incidence and resolution of CRS and neurological events beyond two weeks following axi-cel infusion in relapsed/refractory LBCL.

Dr Garfall on Ide-Cel and Lenalidomide Maintenance in Myeloma After Suboptimal ASCT Response

February 17th 2025

Alfred L. Garfall, MD, MS, discusses data for ide-cel and lenalidomide maintenance in multiple myeloma following a suboptimal response to ASCT and lenalidomide.

Dr Merseburger on Real-World Outcomes With First-Line Axitinib Plus Avelumab in RCC

February 16th 2025

Axel Merseburger, MD, PhD, discusses the real-world efficacy and safety of first-line avelumab plus axitinib in advanced renal cell carcinoma.

Dr Gupta on Updated Data With Enfortumab Vedotin Plus Pembrolizumab in Urothelial Cancer

February 16th 2025

Shilpa Gupta, MD, discusses updated data with enfortumab vedotin plus pembrolizumab in previously untreated urothelial carcinoma.

Drs Al Malki and Auletta on PTCy GVHD Prophylaxis in Patients With HLA-UUMD

February 15th 2025

Monzr Al Malki, MD and Jeffery J. Auletta, MD discuss evaluating PTCy-based GVHD prophylaxis in hematologic malignancies.

Dr Meric-Bernstam on the Efficacy and Safety of Dato-DXd in Metastatic Urothelial Cancer

February 15th 2025

Dr Pothuri on the Current Treatment Paradigm in Endometrial Cancer

February 14th 2025

Bhavana Pothuri, MD, discusses the current treatment paradigm in endometrial cancer and the targeted therapies currently being investigated.

Dr Spencer on the Rationale of Evaluating a Novel CAR T-Cell Product in Pancreatic Cancer

February 14th 2025

Kristen Spencer, DO, details the rationale of the phase 1/2 EVEREST-2 trial evaluating the novel CAR T product A2B694 in pancreatic cancer.

Dr Albigès on Survival Outcomes With Cabozantinib Plus Nivolumab and Ipilimumab in RCC

February 14th 2025

Laurence Albigès, MD, PhD discusses final OS data and biomarker analyses with cabozantinib plus nivolumab and ipilimumab in intermediate- or poor-risk RCC.

Joseph on the Effects of Resistance Training on Fatigue and Pain in Multiple Myeloma

February 14th 2025

Janine Joseph, MS, MBA, discusses the effects of resistance training interventions on fatigue and pain levels in patients with multiple myeloma.

Dr Shah on Efficacy Data for Zamto-Cel in R/R DLBCL

February 14th 2025

Nirav Shah, MD, MSHP, discusses evaluating zamtocabtagene autoleucel in patients with relapsed/refractory diffuse large B-cell lymphoma

Dr Dholaria on the Safety and Efficacy of P-BCMA-ALLO1 in R/R Myeloma

February 14th 2025

Dr Dholaria discusses the phase 1 trial of P-BCMA-ALLO1, highlighting high response rates, rapid CAR T-cell expansion, and a favorable safety profile in RRMM.

Dr Ahmed on NKTR-255 With CD19-Directed CAR T-Cell Therapy in R/R LBCL

February 14th 2025

Sairah Ahmed, MD, discusses evaluating NKTR-255 in combination with CD19-directed CAR T-cell therapy in patients with relapsed/refractory large B-cell lymphoma.